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Purpose: This study aimed to assess self-reported adherence and associated factors to isoniazid 
preventive therapy (IPT) for latent tuberculosis among people living with HIV/AIDS (PLWHA) 
at health centers in Gondar town, North West Ethiopia.
Patients and methods: An institution-based prospective cross-sectional study was conducted 
from March 10 to June 11, 2016. A total of 154 eligible participants were included in the study, 
using the simple random sampling method, from the available four health centers and one 
teaching referral hospital that provided antiretroviral therapy (ART) for HIV/AIDS patients. 
Adherence was measured by self-report of isoniazid (INH) tablets taken for the preceding 7 days. 
Participants were recruited through in-depth interviews. The collected data were entered and 
analyzed using the statistical packages for social sciences (SPSS) version 20.
Results: The adherence level to IPT was 90.3% for the last 7 days of the study. ART was initi-
ated for 84.4%, and all of them were on a first-line regimen. Isoniazid-related side effects were 
reported by 48 (31.2%) participants, of which the most commonly identified were abdominal pain, 
vomiting, skin rash, jaundice, and numbness. Only 3 (2%) participants discontinued from the 
study. In the bivariate logistic regression analysis, respondents who had received an explanation 
about IPT were 83% times more likely to be adherent compared to those who had not received 
it (95% CI, AOR: 0.266 [0.23–3.127]). Respondents who had taken IPT for $5 months were 
more likely to be adherent than those who had taken it for 1–2 months [95% CI, COR: 1.484]. 
On the other hand, respondents who experienced side effects were 36% less likely to be adher-
ent compared to those who did not experience any.
Conclusion: The level of adherence to IPT among PLWHA was high. Among the predictors 
reported, carelessness and/or forgetfulness, side effects, and absence from home were the major 
factors identified for being nonadherent. Health professionals and the Ministry of Health should 
design and deliver appropriate health education tips and messages. Moreover, counseling of 
patients who are in their first 2 months of therapy should be strengthened further.
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Introduction
Tuberculosis (TB) is the leading and most common opportunistic infection and cause 
of mortality in people living with HIV/AIDS (PLWHA). The risk of developing TB 
among PLWHA is 21–34 times greater than among those without HIV infection.1
The interaction between TB and HIV/AIDS is bidirectional, with each disease 
potentiating the adverse effects of the other. This, in turn, affects the prognosis of 
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patients and complicates clinical diagnosis and management 
plans through unusual presentation of symptoms, adverse 
drug reactions, drug–drug interactions, and overlapping 
drug toxicities between anti-TB drugs and highly active 
antiretroviral therapy.2–4 Coinfection with TB and HIV/AIDS 
contributes significantly to the burden on health systems in 
the developing world and complicates and thwarts efforts 
aimed at achieving globally set development and health 
objectives.2–5
Among the collaborative TB/HIV activities by World 
Health Organization (WHO) is to have 100% coverage of 
isoniazid preventive therapy (IPT) for PLWHA attending 
HIV care services among those eligible by 2015.6,7
IPT is the provision of the drug called isoniazid to people 
at high risk of developing active tuberculosis.8 The current 
recommended dose of IPT for adults is 300 mg of isoniazid 
per day for 6 months, with 36 months conditionally recom-
mended in areas of high TB prevalence and transmission.8 
Adolescents and adults living with HIV/AIDS should be 
screened with the WHO checklist for TB symptoms to rule 
out active TB infection. Those reporting one or more symp-
toms might have active TB and should be further evaluated 
and then either treated for TB or, if active TB is ruled out, 
placed on IPT. Those reporting none of the symptoms should 
also be placed on IPT.9
To counter the incidence of TB/HIV coinfection, which 
is about 27.7% in the Amhara region, Ethiopia has developed 
strategies for TB/HIV col laborative activities since 2002. 
However, no pub lished explanations have defined the role of 
these collab orative efforts in strengthening linkages between 
HIV/AIDS and TB management units at the point-of-care 
level; this supports the rates of HIV testing and linkage to 
cotrimoxazole preventive therapy being higher than screen-
ing HIV posi tives for TB, initiation of IPT, linkages, referral, 
and TB diagnostic capacity.10,11
In 2011, WHO recommended that patients infected by 
HIV/AIDS in resource-limited settings should be placed on 
IPT in order to reduce the incidence of TB.8
Studies on IPT delivery have revealed variable rates 
of acceptance of and adherence to TB preventive therapy 
among populations at risk for TB. The overall adherence 
rate for IPT was only 45% in a 2010 study among patients 
attending chest clinics in New York City.12 On the other hand, 
the IPT completion rate among HIV-infected patients with a 
positive tuberculin skin test (TST) who had counseling and 
transport reimbursement was 87% in a study done in Dar es 
Salaam, Tanzania.13 Adherence to IPT in TST-positive and 
non-TST-screened HIV-infected subjects in Thailand was 
84.5 and 79.7% by self-reporting, and 81.8 and 73.9% by pill 
count monitoring.14 In 2014, a study on IPT adherence rate 
reported 86.5% of adherence in 1 month among HIV-infected 
patients in Ethiopia.10
Good adherence to IPT has been attributed to counseling 
before initiation of therapy, regular attendance at follow-up 
clinics, and freedom to take INH publicly.11 Other factors 
shown to affect IPT adherence among HIV-infected patients 
include beliefs about INH safety, understanding of IPT 
rationale, and concerns about potential INH side effects. 
Moreover, patient denial of HIV infection, concerns regard-
ing concurrent use of highly active antiretroviral therapy, 
and HIV/AIDS-related stigma are also relevant.15,16 Directly 
observed preventive therapy and shorter-duration regimens 
for preventive therapy have both been found to improve treat-
ment adherence rates.17 Barriers to the implementation of IPT 
have been found to be connected to both patient factors, as 
mentioned earlier, and health care system factors.18
Several studies reported that nonadherence to therapy 
is the principal problem in the control of TB in developing 
countries. The dual infection of HIV/AIDS and tuberculosis 
presents further adherence problems because of adverse 
effects and high pill burden. Adherence to therapy is the 
key to success.11,19,20
The evidence generated from this study is crucial to 
provide a basis for possible TB/HIV program interventions 
and the management of nonadherence to IPT. Therefore, the 
aim of this study was to assess self-reported adherence and 
associated factors to IPT for latent TB among PLWHA at 
health centers in Gondar town, North West Ethiopia.
Materials and methods
study design and setting
An institution-based prospective cross-sectional study was 
conducted at health centers located in Gondar town. The town 
has one referral and teaching hospital, one private general 
hospital, nine health centers, and many private clinics. Of 
these, only four health centers and one referral and teaching 
hospital are providing ART medications to the patients.
sample size determination and sampling 
procedure
The sample size was determined by using a single mean 
formula.21
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where n = the required number of sample size
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Z = the standard normal distribution designed 95% 
confidence, usually Z =1.96
p = percentage of patient adherence rate of IPT from 
previous study in Ethiopia, which is 0.895
d = degree of accuracy, usually 5%.
Expecting an overall adherence rate of 89.5% at a 95% 
confidence interval, and after adding 5% of the calculated 
sample size for possible nonresponse, 154 patients were 
interviewed. All the four health centers and one referral 
and teaching hospital that are providing ART medications 
were included in the study. Then the number of patients to 
be included in the study from each health center and refer-
ral hospital was calculated on the basis of the average daily 
patient flow to each, and this was used to proportionally allo-
cate the calculated total sample size to the health centers and 
referral hospital. The study was conducted during the period 
March 10 to June 11, 2016, and all patients who fulfilled the 
inclusion criteria and were available during the study period 
were included in the analysis.
Operational definitions
nonadherence
Failed to take .80% or missed $ two doses of INH pills 
prescribed in the last 7 days (1 week) prior to the interview.
Adherence
Able to take $80% of the prescribed INH pills in the last 
7 days (1 week) prior to the interview.
Carelessness: lack of attention or consideration.
Data collection and management
The data collection tool used in the study was adopted from 
previous studies and prepared in English. This was translated 
into the Amharic local language and then back into English to 
ensure that the translated version gave the proper meaning. The 
data collection instrument was pretested on 10 patients who 
were not included in the final analysis, and relevant modifica-
tions were instituted before the commencement of actual data 
collection. The data were collected by four principal investiga-
tors through interviewer-administered questionnaires and face-
to-face interviews by explaining what the questions meant to 
those who were unable to read and/or write. The investigators 
who collected the data were trained in using the instrument 
and in approaching the patients and securing their permission 
for interviews prior to the data collection process.
Data entry and analysis
The data collected using the quantitative method were 
cleaned, entered, and analyzed using IBM SPSS Statistics 
for Windows, version 20.0 (Armonk, NY, USA). In this 
study, sociodemographic characteristics, levels of adherence, 
and associated factors were described using frequencies, 
percentages, mean, and standard deviation (SD). Binary 
logistic regression was employed to assess the factors asso-
ciated with adherence, and P-values of less than 0.05 and 
95% confidence intervals (CI) were used as cutoff points to 
determine the statistical significance of associations among 
different variables.
ethical consideration
Ethical approval was obtained from the research and ethics 
review committee of the School of Pharmacy, University 
of Gondar, to conduct the study. Written informed consent 
was also obtained from each respondent after the purpose of 
the study had been explained. They were also informed that 
participation was vol untary and they could withdraw from the 
study at any stage if they desired. Participants’ confidentiality 
was guaranteed by not recording their personal identifiers on 
the questionnaire.
Results
sociodemographic characteristics of 
respondents
All the 154 interview guides/questionnaires of the sample 
were included in the analysis, making the response rate 100%. 
The participants had a mean age of 37.7 years and an SD 
of 8.97 years. Nearly half (48.1%) of the participants were 
females, and about 2.7% were pregnant. The majority (93.5%) 
of the respondents were Amhara by ethnicity and Orthodox 
Christian religion followers (90.3%). More than two-thirds 
(68.2%) of the participants had completed their primary 
education and lived in families of five or fewer members 
(76.6%). About one-third (29.2%) of the participants were 
self-employed and spent an average of 15–30 minutes to 
reach the health centers (68.2%) (Table 1).
About one-third (31.2%) of the participants experienced 
INH-associated adverse drug reactions (ADRs), of which 
abdominal pain, vomiting, skin rash, jaundice, and numbness 
were the most commonly identified. More than one-third 
(38.3%) of the participants drank alcohol while they were on 
medication; among these, 13% of them drank up to 3 units 
of alcohol 2–3 times per week.
Patients report on adherence and 
associated factors
About 84.4% of the patients were on IPT-initiated ART, all of 
whom were on first-line ART regimen. INH-related common 
side effects were reported by 48 (31.2%) of the participants, 
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of which abdominal pain, vomiting, skin rash, jaundice, 
and numbness were the most commonly identified. Among 
the participants who experienced one or more of the above 
symptoms, only 3 (2%) discontinued INH, which showed that 
most who had mild abdominal pain and vomiting continued 
taking INH. In terms of occupation, the maximum percent-
age of nonadherence was observed among government 
employees, merchants, and servants (Table 2).
The level of self-reported adherence rate of IPT was 
found to be 90.3% with 95% CI (86.1–92.3). In the bivariate 
logistic regression analysis, respondents who did not receive 
any explanation about IPT had 83% lower odds of being 
adherent compared to those who received an explanation 
[95% CI, AOR: 0.266 (0.23–3.127)]. Respondents who took 
IPT for $5 months were more likely to be adherent than those 
who took it for 1–2 months [95% CI, COR: 1.484]. On the 
other hand, respondents who experienced side effects had 
36% lower odds of being adherent compared to those who 
experienced none (Table 3).
reasons for nonadherence
The most frequently mentioned reasons for being non-
adherent were carelessness and forgetfulness (33%), side 
effects (20%), and being away from their residential areas 
or homes (20%) (Figure 1).
Discussion
This study attempted to assess the level of IPT adherence and 
the available evidence regarding factors that hinder adher-
ence to TB preventive therapy among PLWHA in selected 
health centers located in Gondar town. The study found an 
adherence rate of 90.3%, which was in agreement with the 
adherence level reported from a study conducted in Addis 
Ababa (89.5%).10 However, it was higher than the level of 
adherence reported from South Africa, which was 72%.22 This 
might be because the level of adherence in the South African 
study was measured by the more objective method, called the 
Arkansas method, which is laboratory based (biochemical 
test). About 90.3% of the study participants had taken at least 
80% of their prescribed isoniazid doses in the 7 days prior 
to the study. This was similar to the findings of studies done 
in Addis Ababa, Diredawa, and Cambodia, where the levels 
were 89.5%, 86%, and 86.5%, respectively.10,23,24
Among the reasons for good adherence, explanation and 
counseling about IPT and TB secondary to HIV/AIDS was 
a major one, and most of the adherent participants had a 
good understanding of the benefits of IPT from their health 
providers. This means that providing sound counseling peri-
odically on the importance of IPT and adherence will lead 
to the required knowledge and understanding. Associated 
with this, some of them thought that isoniazid is effective in 
Table 1 sociodemographic characteristics of hiV-positive 
patients on isoniazid preventive therapy in gondar, 2016
Variables Categories Frequency  
(n=154)
Percent
sex Male 80 51.9
Female 74 48.1
Age 18–30 81 54.5
31–40 51 33.1
.40 19 12.3
level of education illiterate 10 6.5
Primary school 105 68.2
secondary school 28 18.2
Diploma and above 11 7.1
religion Orthodox 139 90.1
Protestant 1 0.6
Muslim 14 9.1
ethnicity Amhara 144 93.5
Oromo 2 1.2
Tigre 7 4.5
gurage 1 0.6
Family size ,5 118 76.6
6–10 33 21.4
.10 3 1.9
Occupation self-employed 45 29.2
government  
employed
26 16.9
housewives 33 21.4
Merchants 37 24.0
Farmers 11 7.1
students 2 1.3
Monthly income ,250 eTB 71 46.1
251–999 eTB 47 30.5
.1,000 eTB 36 23.4
WhO hiV/AiDs stage 1 and 2 36 23.4
3 116 75.3
4 2 1.3
Note: 1 UsD =21.85 Birr.
Abbreviations: eTB, ethiopian Birr; UsD, United states dollar; WhO, World 
health Organization.
Table 2 cross-tabulation of respondents’ adherence with their 
occupation, gondar, 2016
Occupation Adherence Total Percent
Adherent (%) Nonadherent (%)
students 2 (1.30) 0 (0.0) 2 1.30
Merchants 33 (21.43) 4 (2.60) 37 24.03
housewives 31 (20.13) 2 (1.30) 33 21.43
Farmers 11 (7.14) 0 (0.0) 11 7.14
government  
employees
21 (13.64) 5 (3.25) 26 16.88
servants 41 (26.62) 4 (2.60) 45 29.22
Total 139 (90.26) 15 (9.74) 154 100
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reducing or lowering blood HIV viral load or concentration, 
and in preventing other HIV/AIDS-related complications.
In the binary logistic regression analysis, patients who 
took IPT for $5 months were more likely to be adherent than 
those who took it for about 1–2 months. A similar finding 
was reported by the study conducted in Addis Ababa.10 This 
was probably because the repeated counseling services that 
the patient got from the health facilities during their long 
follow-up period made them more adherent.
Among the reasons for nonadherence, carelessness and 
forgetfulness (33%) to take medication was the major reason 
Table 3 Factors associated with iPT adherence among hiV-positive patients in gondar, 2016
Variables Adherence OR (95% CI)
Yes No Crude Adjusted
sex
Male 73 7 0.79 (0.27–2.30) 1.39 (0.20–9.56)
Female 66 8 1 1
Age
18–30 75 9 1 1
31–40 46 5 2.16 (0.26–18.16) 1.16 (0.23–5.92)
.40 18 1 1.96 (0.21–17.92) 0.44 (0.34–6.50)
Occupation
self-employed 52 4 1 1
government employer 21 5 1.24 (0.28–5.35) 1.38 (0.18–10.23)
housewives 31 2 0.66 (0.11–3.84) 0.38 (0.03–4.37)
Merchants 33 4 2.44 (0.59–10.05) 3.941 (0.29–52.95)
students 2 0 0.000 0.000
Duration of iPT
1–2 months 39 6 1 1
$3 months 100 9 2.48 (0.37–18.26) 0.09 (0.10–0.79)
explanation about iPT regimen
Yes 105 13 1 1
no 34 2 0.47 (0.10–2.21) 0.26 (0.23–3.12)
inh may be dangerous to your health
strongly disagree 33 3 1 1
strongly agree 4 3 8.5 (1.64–44.03) 9.44 (0.62–128.48)
Do not know 102 9 1.09 (0.28–4.30) 2.45 (0.37–15.99)
chance of getting sick from TB without treatment
high 107 17 1 1
Average/below average 19 0 1.26 (0.25–6.43) 8.79 (0.85–91.08)
Do not know 13 2 0.00 0.00
side effects
Yes 45 3 0.24 (0.07–0.74) 0.64 (0.27–10.03)
no 100 6 1 1
ArT status
Pre-ArT 16 8 0.24 (0.07–0.73) 1.68 (0.27–10.03)
On ArT 109 21 1 1
ArT regimen
AZT+3Tc+nVP 85 8 1 1
AZT+3Tc+eFV 15 4 0.84 (0.16–4.33) 0.08 (0.003–2.17)
TDF+3Tc+nVP 11 1 0.429 (0.03–5.12) 0.144 (0.015–1.42)
TDF+3Tc+eFV 18 12 2.4 (0.38–14.97) 1.114 (0.09–13.21)
inh makes me tired
Yes 79 11 0.48 (0.14–1.58) 1.59 (0.27–9.42)
no 60 4 1 1
Abbreviations: AZT, zidovudine; ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; OR, overall ratio; INH, isonizid; IPT, isoniazid preventive therapy; 
nVP, nevirapine; TB, tuberculosis; Tc, lamivudine; TDF, tenofovir.
Figure 1 reasons for nonadherence among hiV-positive patients, gondar, 2016.
Abbreviation: inh, isonizid.
&DUHOHVVQHVV
6LGHHIIHFWV%HLQJWRRLOOWRWDNHWKHPHGLFDWLRQ
%HLQJDZD\IURPKRPH
1RWVXUHZKHQWRWDNH,1+SLOOV
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followed by experiencing ADRs (20%) and being away 
from home (20%). While taking the medication, some of 
the patients experiencing ADRs stopped taking the medica-
tion. This could be because the ADRs were not minor or 
self-limited and because some, like acute hepatitis, tingling, 
and numbness (associated peripheral neuropathy), were not 
effectively controlled. Along with this, a guideline developed 
in South Africa for treatment of TB also recommends that in 
cases of mild peripheral neuropathy, pyridoxine (vitamin B6) 
must be given and increased from 25 mg to 100 mg daily 
until the symptoms disappear. If the peripheral neuropathy 
is severe or worsens, then isoniazid should be discontinued 
immediately.22
If the patient develops signs or symptoms suggestive of 
hepatitis, isoniazid should be stopped immediately, a blood 
sample should be sent for liver function tests (ALT test is 
adequate), and the patient should be referred immediately to 
a medical officer.22 On the other hand, worsening or develop-
ing acute illness, pneumonia, and gastrointestinal infections 
were also among the contributing reasons for nonadherence. 
Participants who developed an acute illness might have taken 
only drugs that treated the illness and ignored their preventive 
treatment with isoniazid.
Not being sure at which time to take isoniazid pills was 
also a reason for nonadherence (14%). Similarly, a study 
conducted in Thailand also revealed that the perceived 
side effects of isoniazid and misunderstanding about the 
duration of the preventive therapy were reasons for being 
nonadherent.25
With regard to occupation as a factor in nonadherence, 
self-employed participants such as merchants and servants 
showed higher nonadherence rates. This might be attributed 
to their jobs, since they might have been leaving their pills 
at home, and searching for jobs might have been a barrier 
to taking their INH pills.25 Being employed in government 
jobs may also have been a factor in nonadherence, due to 
carelessness in taking INH pills, fear of stigma at the work-
place, and less confidentiality.
Limitations of the study
This study tried to assess the level of IPT adherence using 
a self-reported survey, which is subject to recall and social 
desirability biases. The other limitation was that no standard 
questionnaire was used to measure the level of adherence; 
instead, a cutoff point of adherence of 80% and above was 
used as a standard from previous studies that were conducted 
in South Africa and Addis Ababa. Moreover, data on CD4 
level and HIV viral load test were not obtained.
Conclusion
The overall level of adherence to IPT is high. Patients who 
took INH for $5 months and did not experience any side 
effects were found to be more likely to be adherent than those 
who took it between 1 and 2 months and experienced side 
effects. Among the predictors reported for being nonadher-
ent, carelessness and/or forgetfulness were the major ones. 
Health professionals and the Ministry of Health should design 
and deliver appropriate health education tips and messages 
on the aforementioned risk factors for patients to promote 
better adherence. Moreover, counseling should focus on 
patients who are in the first and second months of follow-up 
and advise them to develop habits such as using cell phones 
and watches with alarms and memory aids such as diaries as 
reminders are very important to improve their adherence.
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